BiondVax

Uses your system voice; voice and rate in settings.

Snapshot

≈ 2 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

BiondVax Pharmaceuticals Ltd. is an Israeli biopharmaceutical company focused on developing and manufacturing immunotherapeutic products, primarily for the treatment of infectious diseases and autoimmune diseases. In collaboration with the Max Planck Institute for Multidisciplinary Sciences (MPG) and the University Medical Center Göttingen (UMG), both in Germany, BiondVax develops nanosized antibody (NanoAb) therapies for diseases such as COVID-19, asthma and psoriasis.

BiondVax Pharmaceuticals Ltd. is an Israeli biopharmaceutical company focused on developing and manufacturing immunotherapeutic products, primarily for the treatment of infectious diseases and autoimmune diseases. In collaboration with the Max Planck Institute for Multidisciplinary Sciences (MPG) and the University Medical Center Göttingen (UMG), both in Germany, BiondVax develops nanosized antibody (NanoAb) therapies for diseases such as COVID-19, asthma and psoriasis.

History

Since its founding, BiondVax has executed eight clinical trials, including a seven-country, 12,400-participant Phase 3 trial of a prior influenza vaccine candidate, and owns and operates a biologics manufacturing facility for housing its laboratories, production facilities and offices. In 2017, their influenza vaccine was found in a Phase IIb trial to have "broad strain coverage."

In December 2021, BiondVax signed definitive agreements with the Max Planck Society – parent organization of the Max Planck Institute for Multidisciplinary Sciences – and the UMG to enter into a strategic collaboration for the development and commercialization of COVID-19 NanoAbs.

See also

COVID-19 vaccines Health care in Israel Science and technology in Israel

Text derived from https://en.wikipedia.org/w/index.php?oldid=1359344413 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

1 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.